FactEvidence 1
share price changerose more than 3%
No public evidence summary is available.
GDELT Global Knowledge Graph · 2026-10-08 05:15
View evidence
- MediaGDELT Global Knowledge Graph2026-10-08 05:15View source
Company
Ultragenyx Pharmaceutical
Description
- Headquarters
- US
Claims
Read the assertion alongside its sources. Expand a row to inspect the evidence.
FactEvidence 1
prv sale agreement value$210 million
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million.
GlobeNewswire public company news · 2026-10-07 20:30
View evidence
- CompanyGlobeNewswire public company news2026-10-07 20:30
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million.
View source
Showing 1 to 2 of 2
Market and valuation
Valuation data is available on Pro and Research.
Included in ProNot available: Company signals · Relations · Financials · Filings · Guidance